The solution and solid state stability and excipient compatibility of parthenolide in feverfew

AAPS PharmSciTech

Volumn 8, Issue 4, 2007, Pages

  Jin, Ping ^a,b   Madieh, Shadi ^a,c   Augsburger, Larry L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNITED STATES PHARMACOPEIA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Botanical; Excipient compatibility; Feverfew; Parthenolide; Stability

Indexed keywords

BUFFER; EXCIPIENT; PARTHENOLIDE; TANACETUM PARTHENIUM EXTRACT; NONSTEROID ANTIINFLAMMATORY AGENT; PLANT MEDICINAL PRODUCT; SESQUITERPENE; WATER;

AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DEGRADATION KINETICS; DRUG SOLUTION; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; HUMIDITY; MOISTURE; PH MEASUREMENT; POWDER; SOLID STATE; STORAGE TEMPERATURE; TANACETUM PARTHENIUM; CHEMISTRY; DRUG FORMULATION; HYDROLYSIS; KINETICS; METHODOLOGY; PH; PHARMACEUTICS; SOLUTION AND SOLUBILITY; TEMPERATURE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; HUMIDITY; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KINETICS; PLANT PREPARATIONS; POWDERS; SESQUITERPENES; SOLUTIONS; TANACETUM PARTHENIUM; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; WATER;

EID: 37349117583     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt0804105     Document Type: Article

References (18)

1. Kemper KJ. Feverfew (Tanacetum parthenium). Available at: http://www.longwoodherbal.org/feverfew/feverfew.pdf. Accessed November 2, 2007.
2. Abourashed EA, Khan IA, Abourashed EA, Khan IA. Determination of parthenolide in selected feverfew products by liquid chromatography. J AOAC Int. 2000;83:789-792.
3. Draves AH, Walker SE. Parthenolide content of Canadian commerical feverfew preparations: Label claims are misleading in most cases. Can Pharm J. 2004;136:23-30.
4. Nelson MH, Cobb SE, Shelton J. Variations in parthenolide content and daily dose of feverfew products. Am J Health Syst Pharm. 2002; 59:1527-1531.
5. Jin P, Madieh S, Augsburger LL. Selected physical and chemical properties of feverfew (tanacetum parthenium) extracts important for formulated product quality and performance. AAPS PharmSciTech. In press.
6. Hendricks H, Anderson-Wildeboer Y, Engels G, Bos R, Woerdenbag H. The content of parthenolide and its yield per plant during the growth of Tanacetum parthenium. Planta Med. 1997;63:356-359.
7. Rushing JW, Hassell RL, Dufault RJ. Drying temperature and developmental stage at harvest influence the parthenolide content of feverfew leaves and stems. Acta Hort. 2004;629:167-173.
8. Kaplan M, Simmonds MR, Davidson G. Comparison of supercritical fluid and solvent extraction of feverfew (Tanacetum parthenium). Turk J Chem. 2002;26:473-480.
9. Tanko HM, Carrier DJ, Sokhansanj S, Crowe TG. Effects of drying temperature and storage on parthenolide concentration of feverfew ( Tanacetum parthenium L.) leaves. Journal of Nutraceuticals, Functional and Medicinal Foods. 2003;4:27-37.
10. Heptinstall S, Awang DV, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products. J Pharm Pharmacol. 1992;44: 391-395.
11. Smith RM, Burford MD. Supercritical fluid extraction and gas chromatographic determination of the sesquiterpene lacatone parthenolide in the medicinal herb feverfew. J Chromatog. 1992;627: 255-261.
12. Stability Testing of New Drug Substances and Products. ICH Expert Working Group. Available at: http://www.ich.org/LOB/media/ MEDIA419.pdf. Accessed December 6, 2007.
13. Castaneda-Acosta J, Fischer NH, Vargas D. Biomimetic transformations of parthenolide. J Nat Prod. 1993;56:90-98.
14. Neukirch H, Kaneider NC, Wiedermann CJ, Guerriero A, D'Ambrosio M. Parthenolide and its photochemically synthesized 1(10) Z isomer: chemical reactivity and structure-activity relationship studies in human leucocyte chemotaxis. Bioorg Med Chem. 2003; 11: 1503-1510.
15. Kopelman SH, Augsburger LL. Excipient compatibility study of Hypericum perforatum extract (St. John's wort) using similarity metrics to track phytochemical profile changes. Int J Pharm. 2002;237:35-46.
16. Serajuddin AT, Thakur AB, Ghoshal RN, et al. Selection of solid dosage form composition through drug-excipient compatibility testing. J Pharm Sci. 1999;88:696-704.
17. Van Dooren AA, Duphar BV. Design for drug-excipient interaction studies. Drug Dev Ind Pharm. 1983;9:43-55.
18. Patel N, Patel I, Cutie A, Wadke D, Monkhouse D, Reier G. The effect of selected direct compression excipients on the stability of aspirin as a model hydrolyzable drug. Drug Dev Ind Pharm. 1988;14:77-98.